Drugs / GSK3903133A
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04062669 | Aug 2019 → Jul 2021 | viral infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3903133A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04062669 ↗ |
| Known as | RG SAM (CNE) | “Low dose formulation of RG SAM (CNE) vaccine (GSK3903133A)” NCT04062669 ↗ |
| Modality | Vaccine | “Experimental Rabies Vaccine” NCT04062669 ↗ |
| Route | Intramuscular | “administered intramuscularly at Day 1.” NCT04062669 ↗ |